Johnson & Johnson will not receive FDA approval for a new indication for RYBREVANT (amivantamab-vmjw) by November 24, 2026.
Posted 2026-09-25 — 60 days before the deadline, stated before the outcome.
The claim
Johnson & Johnson will not receive FDA approval for a new indication for RYBREVANT (amivantamab-vmjw) by November 24, 2026.
Reasoning trace
- The PAPILLON trial's final overall-survival analysis was released in late September 2026.
- FDA review cycles for major oncology indications typically require 3 to 6 months of evaluation post-data release.
- Therefore, a formal approval decision for a new indication is not resolvable within the remaining 2-month window.
Evidence so far
0 confirming · 0 denying signals · 0 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-09-26) — 80% at mint → 80% today.
What to watch
- precondition The FDA publishes a PDUFA date or public notice indicating that a review of a new indication for RYBREVANT (amivantamab-vmjw) is scheduled to conclude on or before November 24, 2026.
- leading indicator The FDA issues a public statement or press release announcing the approval of a new indication for RYBREVANT (amivantamab-vmjw).
- precondition The US Food and Drug Administration (FDA) publishes a public approval letter or press release for a new indication for RYBREVANT (amivantamab-vmjw).
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.